News Release

The growth of radionanotargeting towards clinical accuracy oncology

A festschrift in honor of Kalevi Kairemo

Book Announcement

Bentham Science Publishers

This book “The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo” contains a unique collection of articles starting from radionanotargeting and theragnostics leading to imaging and therapy, which includes sections for thyroid cancer, head and neck cancer, genitourinary cancers and neuroendocrine neoplasms. Theragnostics, nanoparticles and precision oncology have also been covered in their own segments. The supporting sciences consists metabolic imaging, cardiovascular radionuclide imaging, combined and bone therapies. Finally Professor Kairemo’s own memoir “Seven decades in health care” and memoirs from colleagues including a personal introduction to Kalevi Kairemo with a photographic cavalcade opens the world of multitasking person with multidisciplinary approach to science, development of significant expertise across the fields of chemistry, biology, engineering, physics and clinical medicine. This book is excellent for specialists in imaging and clinical oncology in expanding their understanding of the role of radionuclides, and it should belong in archive of all persons including trainees in radionuclides field.

 

A Festschrift in Honor of Kalevi Kairemo

Prof. Kairemo graduated with an MSc (Eng.) degree from Helsinki University of Technology in 1980 before undertaking medical training (MD (86), Ph.D. (93)) at the University of Helsinki, Finland. He undertook specialist training in Clinical Chemistry (94), Nuclear Medicine (96), Health Care Administration (02) and Clinical Pharmacology (06) at Helsinki University Central Hospital. He attained a post-doctoral research fellowship at Memorial Sloan-Kettering Cancer Center in 1989-93 in New York. 

Prof. Kairemo has held posts as Professor of Clinical Chemistry at the Norwegian University of Science and Technology (1998-9), Professor of Nuclear Medicine at Uppsala University Hospital in Sweden (2001-5), and as Head of the Nuclear Medicine Division, Department of Oncology at Helsinki University Central Hospital (2004-9). From 2009-2018, he has held the position of the Chief of Nuclear Medicine and Molecular Radiotherapy (Theragnostics) at the Docrates Cancer Center in Helsinki.  From 2015, he acted as the Visiting Professor in the Nuclear Medicine Department, The University of Texas, MD Anderson Cancer Center, Houston, TX; his last visit was in 2019.

Prof. Kairemo has also held posts in the industry as Medical Director of Cancer Targeting Technologies (2001-6), Medical Director of Imanext Ltd (2006-8), and Clinical Director at Advanced Accelerator Applications SA in 2009 (now Novartis Co.).

Prof. Kairemo has vast experience in the development of tumor-seeking compounds, including monoclonal antibodies, specific phage-display peptides and cytotoxic drugs, and he has coordinated several EU Research Programmed proposals, including the National Coordinator and Management Committee Member for the European Union COST Action Project (BM 0607, Targeted Radionuclide Therapy) from 2007-11. He also served as WARMTH Governing Body Member in 2009-12 and again in 2018. He has also been active in hosting short-term scientific visits for students from developing countries.

Besides a few patents, Prof. Kairemo has published more than 250 original publications in peer-reviewed journals (H-index 34). He received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) in 2012, and was appointed the President of the 7th International Conference on Radiopharmaceutical Therapy held in November 2012 in Levi in Finnish Lapland.  In 2014, Dr. Kairemo hosted ISORBE Symposium and Workshop “Cell Labelling and Cell Therapies” in Helsinki. He also organized the International Symposium on Radiopharmaceutical Therapy (WARMTH) in November 2018 in Helsinki.

 

Keywords

Radionuclide therapy, Radionuclide Imaging, Cancer Imaging, Cancer Therapy Chemotherapy,

 

Please visit the link for more information:  https://bit.ly/3vTYwhm

 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.